PTC Therapeutics is a biopharmaceutical company that develops and commercializes medicines for patients with rare disorders. Its portfolio includes commercial products and product candidates in various stages of development, with a focus on rare diseases. The company offers treatments for Duchenne muscular dystrophy, spinal muscular atrophy, and rare diseases in Latin America and the Caribbean. PTC Therapeutics has collaborations with F. Hoffman-La Roche Ltd, the Spinal Muscular Atrophy Foundation, and Akcea Therapeutics, Inc. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.